公开(公告)号：US20230304913A1

公开(公告)日：2023-09-28

申请号：US18181803

申请日：2023-03-10

申请人： Genzyme Corporation

发明人： Victor R. Cairns ,  Jose Ignacio Sancho Chavida ,  Christine DeMaria

IPC分类号： G01N15/14 ,  C12N15/10 ,  C07K16/00 ,  G01N33/50 ,  C12N15/85

CPC分类号： G01N15/14 ,  C12N15/1086 ,  C07K16/00 ,  G01N33/5044 ,  C12N15/85 ,  C07K2317/10 ,  G01N2333/70592 ,  C12N2510/02 ,  G01N2015/149

摘要： Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS). In some aspects, the disclosure provides a drug-selection-free method for batch production of producer cells using FACS. Such batch production methods and compositions can be further utilized to generate clonal populations of producer cells, e.g., for large-scale manufacturing of a polypeptide of interest.

公开(公告)号：US20150259412A1

公开(公告)日：2015-09-17

申请号：US14440703

申请日：2013-03-25

申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

发明人： Leonard Charles Harrison ,  Maryam Rashidi ,  Yuxia Zhang

IPC分类号： C07K16/24 ,  G01N33/50 ,  G01N33/68

CPC分类号： G01N33/6896 ,  A61K38/00 ,  C07K14/70592 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0637 ,  G01N33/502 ,  G01N33/564 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/70592 ,  G01N2800/26 ,  G01N2800/285 ,  G01N2800/50 ,  G01N2800/52

摘要： The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.

摘要翻译： 本公开涉及可溶性CD52糖蛋白在治疗由效应T细胞调节的疾病中的用途，例如败血症或多发性硬化症。 本公开还涉及基于检测受试者中CD52表达水平的诊断方法。

公开(公告)号：US20170121734A1

公开(公告)日：2017-05-04

申请号：US15288050

申请日：2016-10-07

申请人： Genzyme Corporation

发明人： Victor R. Cairns ,  Christine DeMaria ,  Jason Vitko

IPC分类号： C12N15/85

CPC分类号： G01N15/14 ,  C07K16/00 ,  C07K2317/10 ,  C12N15/1086 ,  C12N15/85 ,  C12N2510/02 ,  G01N33/5044 ,  G01N2015/149 ,  G01N2333/70592

摘要： Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.

公开(公告)号：US20170115282A1

公开(公告)日：2017-04-27

申请号：US15317494

申请日：2015-06-09

申请人： CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.)

发明人： Vincent CASTELLA ,  Frédéric GROSJEAN

IPC分类号： G01N33/543

CPC分类号： G01N33/54326 ,  G01N2333/70592

摘要： The invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention concerns a method for separating cells of interest according to a specific marker expressed on their surface.

公开(公告)号：US20090239235A1

公开(公告)日：2009-09-24

申请号：US12441806

申请日：2007-09-18

申请人： Christine DeMaria ,  Scott Estes ,  Kenneth P. Karey ,  Victor Cairns

发明人： Christine DeMaria ,  Scott Estes ,  Kenneth P. Karey ,  Victor Cairns

IPC分类号： C12Q1/68 ,  G01N33/567 ,  C12N5/10

CPC分类号： C12N15/1086 ,  G01N33/537 ,  G01N33/6863 ,  G01N2333/70592 ,  G01N2333/70596

摘要： Methods are disclosed to identify, select and produce a clonal population of recombinant eukaryotic host cells that stably and highly express a polypeptide of interest. Also disclosed herein are products produced by the disclosed methods and assemblies of components useful to conduct the methods.

摘要翻译： 公开了鉴定，选择和产生稳定和高度表达感兴趣的多肽的重组真核宿主细胞的克隆群体的方法。 本文还公开了通过所公开的方法生产的产品和用于实施该方法的部件组件。

公开(公告)号：US10060914B2

公开(公告)日：2018-08-28

申请号：US15317494

申请日：2015-06-09

申请人： CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.)

发明人： Vincent Castella ,  Frédéric Grosjean

IPC分类号： G01N33/543

CPC分类号： G01N33/54326 ,  G01N2333/70592

摘要： The invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention concerns a method for separating cells of interest according to a specific marker expressed on their surface.

公开(公告)号：US20170227441A1

公开(公告)日：2017-08-10

申请号：US15288036

申请日：2016-10-07

申请人： Genzyme Corporation

发明人： Victor R. Cairns ,  Jose Ignacio Sancho Chavida ,  Christine DeMaria

IPC分类号： G01N15/14

CPC分类号： G01N15/14 ,  C07K16/00 ,  C07K2317/10 ,  C12N15/1086 ,  C12N15/85 ,  C12N2510/02 ,  G01N33/5044 ,  G01N2015/149 ,  G01N2333/70592

摘要： Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS). In some aspects, the disclosure provides a drug-selection-free method for batch production of producer cells using FACS. Such batch production methods and compositions can be further utilized to generate clonal populations of producer cells, e.g., for large-scale manufacturing of a polypeptide of interest.

公开(公告)号：US20130095507A1

公开(公告)日：2013-04-18

申请号：US13705944

申请日：2012-12-05

申请人： Genzyme Corporation

发明人： David H. Margolin

IPC分类号： G01N33/68

CPC分类号： G01N33/6854 ,  G01N33/5047 ,  G01N33/6893 ,  G01N2333/635 ,  G01N2333/70592 ,  G01N2800/046

摘要： A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.

摘要翻译： 一种用于鉴定患有发生甲状腺疾病风险的患者的方法，所述患者在用消耗淋巴细胞的方案治疗后发生，包括确定是否存在针对甲状腺过氧化物酶或甲状腺微粒体的抗体存在于患者中，其中如果存在抗体 在患者身上，患者发生甲状腺疾病的风险增加。 一个特定的实施方案是用于鉴定患有多发性硬化症的患者，该患者处于发生甲状腺疾病的风险中，所述甲状腺疾病在用消耗CD52阳性细胞的方案治疗后发生，包括确定是否存在针对甲状腺过氧化物酶或甲状腺微粒体的抗体 在患者体内，如果抗体存在于患者中，则患者处于发展甲状腺疾病的风险中。

公开(公告)号：US20230266325A1

公开(公告)日：2023-08-24

申请号：US18011724

申请日：2021-06-30

申请人： LungLife AI, Inc.

发明人： Paul PAGANO ,  Daniel GRAMAJO-LEVENTON ,  Rebecca REED ,  Shahram TAHVILIAN ,  Lara BADEN ,  Ashley BROWN

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N2333/70592

摘要： The present disclosure provides a method for of determining the level of circulating tumor cells (CTCs) in a sample having blood cells from a patient comprising obtaining a test sample from a human subject; enriching circulating tumor cells (CTC); hybridizing the enriched cells in the sample with labeled nucleic acid probes that hybridize to regions of chromosomal DNA; evaluating the signal pattern for the selected cells by detecting fluorescence in situ hybridization from cells; detecting CTCs based on the pattern of hybridization to the labeled nucleic acid probes to said selected cells; and identifying the subject at risk for the development of lung cancer when the number of CTC per sample is above a predetermined cutoff value.--

公开(公告)号：US20230257825A1

公开(公告)日：2023-08-17

申请号：US18106248

申请日：2023-02-06

申请人： City of Hope

发明人： Peter P. Lee ,  Colt Egelston ,  Weihua Guo ,  Jiayi Tan

IPC分类号： C12Q1/6886 ,  G01N33/569 ,  G01N33/574 ,  A61K45/06

CPC分类号： C12Q1/6886 ,  G01N33/56972 ,  G01N33/57415 ,  A61K45/06 ,  C12Q2600/158 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70592

摘要： The disclosure provides, inter alia, breast cancer biomarkers, methods of detecting exhausted CD8+ T cells in breast cancer patients, methods of detecting CD26+CD4+ T cells in breast cancer patients, methods of treating breast cancer patients, and methods of identifying risk outcomes for breast cancer patients.